skip to main content

Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerBreast CancerSCE Medical Oncology

A patient taking adjuvant abemaciclib with endocrine therapy develops an incidentally detected, haemodynamically stable pulmonary embolus. Anticoagulation is started and the event is CTCAE grade 2. What dose action does the UK product information specify for venous thromboembolism in the early-breast-cancer setting?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Suspend abemaciclib, treat the embolus and consider resumption once clinically stable

For early breast cancer, the Verzenios SmPC directs suspension of abemaciclib for venous thromboembolism of any grade, treatment as clinically indicated and possible resumption when the patient is clinically stable. This differs from metastatic disease, in which grade 1 or 2 VTE requires no dose modification. Automatic permanent discontinuation, dose reduction without interruption, or stopping the endocrine partner does not follow the product-specific table.

Reference: Verzenios 100 mg UK summary of product characteristics (Current UK SmPC, accessed August 2026): https://www.medicines.org.uk/emc/product/11046/smpc